management missing the regulatory space opportunity that is...

management missing the regulatory space opportunity that is unique to them bar one other similar medication......letting it drift along and find its own way is not good enough

Needs to be put before the DEA for 'compound medication' descheduling' approval ....the pediatric ASD phaseI/II data point outcomes ongoing demand this be part of the progress forward ......forget Panda and pans ....
NTI164 fits the requirement for the application perfectly ....
(Cardiolrx is the other potential candidate that could leverage the process through the DEA but they have a more advanced FDA approved trial program in place)

there is a precedent with same DEA compound deschedule classification which make it market available upon DEA tick in this regard - FDA approve process deschedule and speed IND and trail work in conjunction with DEA process would be a strategic master stroke and deserving of this drug candidate ...drive investment without needing placements and dilution...better utilisation of current cash and research resources

Epidiolex is the precedent drug .....NTI164 has far greater potential and it is not being leveraged accordingly imo

something to think about